Webster Equity Partners has entered into a definitive agreement to acquire Lifecore Biomedical in a transaction valued at up to $663.7 million, according to a news release.
Lifecore (Nasdaq: LFCR), founded in 1965 and based in Chaska, Minnesota, is a contract development and manufacturing organization specializing in the development and fill/finish of sterile injectable pharmaceuticals. It is also a manufacturer of injectable-grade hyaluronic acid.
Webster, based in Waltham, Massachusetts, is a middle market private equity firm focused exclusively on healthcare. It typically targets businesses with revenue between $20 million and $200 million. The firm’s identified practice areas are physician practice management, post-acute care, women’s and children’s health, behavioral health and pharma services.
The deal is expected to close at the end of the fourth quarter of 2026. Upon completion, Lifecore’s common stock will be delisted from the Nasdaq stock market
Recent Comments